Glaxosmithkline Pharmaceuticals Ratios

Glaxosmithkline Pharmaceuticals Ltd Ratios

The Glaxosmithkline Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Glaxosmithkline Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Glaxosmithkline Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Glaxosmithkline Pharmaceuticals Ltd (NSE: GLAXO, BSE: 500660) is currently trading at ₹2594.40, with a market capitalization of ₹439.42B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Glaxosmithkline Pharmaceuticals Ltd remains a key stock for fundamental analysis using Glaxosmithkline Pharmaceuticals Ltd Ratios.

Glaxosmithkline Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Glaxosmithkline Pharmaceuticals Ltd P/E ratio currently stands at 52.55, making it one of the most tracked metrics in Glaxosmithkline Pharmaceuticals Ltd Ratios.

Historically, the Glaxosmithkline Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 52.55
• 2023: 55.80
• 2022: 36.73
• 2021: 16.62
• 2020: 68.13

The decline in Glaxosmithkline Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Glaxosmithkline Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 24.98.

Historical P/B trend:

• 2024: 24.98
• 2023: 18.52
• 2022: 12.88
• 2021: 10.58

Glaxosmithkline Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Glaxosmithkline Pharmaceuticals Ltd P/S ratio currently stands at 13, an important part of Glaxosmithkline Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 13
• 2023: 9.53
• 2022: 6.90
• 2021: 8.59

The rising Glaxosmithkline Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 34.62.

Historical Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 34.62
• 2023: 48.75
• 2022: 40.99
• 2021: 32.97
• 2020: 38.58

The declining Glaxosmithkline Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Glaxosmithkline Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Glaxosmithkline Pharmaceuticals Ltd EV currently stands at ₹462.29B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 462.29B
• 2023: 310.57B
• 2022: 207.73B
• 2021: 253.41B

Glaxosmithkline Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Glaxosmithkline Pharmaceuticals Ltd EV/EBITDA ratio is currently 38.86, a key metric in Glaxosmithkline Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 38.86
• 2023: 33.93
• 2022: 25.31
• 2021: 32.81

Higher Glaxosmithkline Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Glaxosmithkline Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Glaxosmithkline Pharmaceuticals Ltd D/E ratio is currently 0.01, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.01
• 2023: 0.01
• 2022: 0.01
• 2021: 0.01

Glaxosmithkline Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Glaxosmithkline Pharmaceuticals Ltd ROE currently stands at 49.75%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 49.75
• 2023: 33.53
• 2022: 27.59
• 2021: 18.30

Glaxosmithkline Pharmaceuticals Ltd demonstrates strong profitability and efficient capital utilization.

Glaxosmithkline Pharmaceuticals Ltd Ratios Analysis Summary

The Glaxosmithkline Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Glaxosmithkline Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Glaxosmithkline Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.